Multiple sclerosis relapsing-remitting

Betaseron Interferon P-lb Berlex Laboratories Relapsing, remitting multiple sclerosis... 

Lyseng-Williamson, K. and Plosker, G. 2002. Management of relapsing-remitting multiple sclerosis - defining the role of subcutaneous recombinant interferon-(3-la (Rebif). Disease Management and Health Outcomes 10(5), 307-325. 

Revel M. Interferon-P in the treatment of relapsing-remitting multiple sclerosis. Pharmacol Ther 2003 100 49-62. 

Rebif (rh IFN-/l-la, produced in CHO cells) Ares-Serono Relapsing/remitting multiple sclerosis 1998 (EU), 2002 (USA)... 

May be useful for relapsing-remitting multiple sclerosis in patients who are not benefiting from, or are intolerant of, interferon p-1 aA> less effective in patients with advanced disease or chronic-progressive multiple sclerosis not a cure for multiple sclerosis and benefits achieved are relatively modest... 

Relapsing-remitting multiple sclerosis Interferon beta-la-. IM 30 meg Avonex once weekly. Subcutaneous Initially 8.8 meg Rebif 3 times/wk, may increase over 4-6 wk to 44 meg Rebif 3 times/wk. Interferon beta-lb-. Subcutaneous 0.25 mg (8 million... 

Knobler, R.L., J.I. Greenstein, K.P. Johnson, ED. Lublin, H.S. Panitch, K. Conway, S.V. Grant-Gorsen, J. Muldoon, S.G. Marcus, J.C. Wallenberg, et al., Systemic recombinant human interferon-beta treatment of relapsing- remitting multiple sclerosis pilot study analysis and six-year follow-up. J Interferon Res, 1993. 13(5) 333-40. 

About 80% of MS patients have an episodic form of the disease called relapsing-remitting multiple sclerosis. An episode typically starts with sensory disturbances, limb weakness, and clumsiness symptoms evolve over several days, stabilize, and then often improve spontaneously or in response to corticosteroids. In the initial phase of the disease, relapses are generally followed by complete or nearly complete clinical recovery. However, persistent signs of CNS dysfunction may develop after a relapse, and the disease... 

Paty, D.W., and D.K. Li, Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology, 1993.43(4) 662-7. 

Indications Treatment of ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations... 

B. Indications and nse Betaseron is indicated for use in ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of chnical exacerbations. The safety and efficacy of Betaseron in chronic-progressive MS has not been fully evaluated. 

Recommended dosage and monitoring requirements For prevention of exacerbations in patients with relapsing-remitting multiple sclerosis, the recommended dose of Betaseron is 0.25 mg injected subcutaneously every other day. 

E. Therapeutic response Two studies evaluated the safety and efficacy of Rebif in patients with relapsing-remitting multiple sclerosis. Study 1 was a placebo-controlled, 2-year trial in 560 patients with multiple sclerosis for at least 1 year. The primary efficacy end point was the number of clinical exacerbations. The mean numbers of exacerbations per patient over 2 years was 1.82 and 1.73 in those who received either 22 pg or 44 pg three times per week compared with a mean number of 2.56 in those who received placebo. The decrease in the number of exacerbations in the Rebif groups compared with the placebo group was statistical significant, but the difference between... 

The effects of prednisone on memory have been assessed (SEDA-21, 413 90). Glucocorticoid-treated patients performed worse than controls in tests of explicit memory. Pulsed intravenous methylprednisolone (2.5 g over 5 days, 5 g over 7 days, or 10 g over 5 days) caused impaired memory in patients with relapsing-remitting multiple sclerosis, but this effect is reversible, according to the results of an Italian study (91). Compared with ten control patients, there was marked selective impairment of explicit memory in 14 patients with relapsing-remitting multiple sclerosis treated with pulsed intravenous methylprednisolone. However, this memory impairment completely resolved 60 days after methylprednisolone treatment. 

Oliveri RL, Sibilia G, Valentino P, Russo C, Romeo N, Quattrone A. Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 1998 97(6) 366-9. 

Martinelli V, Gironi M, Rodegher M, Martino G, Comi G. Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment. Ital J Neurol Sci 1998 19(2) 65-7. 

Murdoch D, Lyseng-Williamson KA. Subcutaneous recombinant interferon-beta-la (Rebif) a review of its use in relapsing-remitting multiple sclerosis. Drum-. 2005 65 1295-1312. 

Andersen O, et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47(4) 895-900... 

Chronic hepatitis B and C Relapsing- remitting multiple sclerosis Chronic granulo- matous disease... 

Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003 362 1184-91. 

Although isolated reports of psychotic delusional symptoms and depression continue to be published (404), recent controlled trials or longitudinal studies have not provided evidence of an increase in depression scores or in the rate of depression in patients treated with interferon beta (SEDA-27, 389). In a meta-analysis of seven trials in 1215 patients with relapsing remitting multiple sclerosis, the incidence of depression was 16% and did not differ between interferon-beta and controls, but the scales used to assess depression were specified in only three trials (405). Using a public reimbursement database for multiple sclerosis, the prevalence and incidence of depression and depression scores were not different in 163 patients treated with interferon beta or glatiramer, but the study was poorly controlled for potential biases (406). Overall, the current data suggest that interferon-beta is not substantially associated with depression. 

Ebers GC, Hommes O, Hughes RAC, et alPRISMS (Prevention of Relapses and Disability by Interferon beta-la Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/remitting multiple sclerosis. Lancet 1998 352(9139) 1498-504. 

Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D Amico R, Rice GP. Interferons in relapsing remitting multiple sclerosis a systematic review. Lancet 2003 361 545-52. 

Gielen A, Kliademi M, Muhallab S, Olsson T, Piehl F (2003) Increased brain-deiived neurotr oplric factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scand J Immunol 57 493 97. 

---